The inhibition of N-acetyltransferase activity and gene expression in human bladder cancer cells (T24) by Shikonin

In Vivo

Volumn 18, Issue 1, 2004, Pages 21-32

  Yeh, Chin Chung ^a,b   Wu, Lii Tzu ^b   Lin, Shuw Yuan ^c   Li, Te Mao ^b   Chung, Jing Gung ^b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

AAF (acetylated aminofluorene); AF (aminofluorene); AF DNA adducts; Arylamine (N acetyl 2 aminofluorene and 2 aminofluorene); Bladder cancer cells

Indexed keywords

2 FLUORENYLAMINE; ACYLTRANSFERASE; BETA ACTIN; MESSENGER RNA; SHIKONIN;

ACETYLATION; AGED; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DNA ADDUCT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; NUCLEOTIDE SEQUENCE; TRANSITIONAL CELL CARCINOMA;

EID: 1342304963     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Wang WJ, Bai JY,Liu DP,Xue LM and Zhu XY: The anti-inflammatory activity of shikonin and its inhibitory effect on leukotriene B4 biosynthesis . Yao Xue Xue Bao 29: 161-165, 1994.
2. Chen X, Yang L, Oppenheim JJ et al: Cellular pharmacology studies of shikonin derivatives. 16: 199-209, 2002.
3. Fu SL, Shang TM and Xiao PG: Analysis of naphthaquinone pigments in Chinese medicinal 'Zicao', Arnebia euchroma. Yao Xue Xue Bao 19: 921-952, 1984.
4. Jian Y, Zhou Y and Zhang H: Quality of Chinese drug Zicao. Zhongg Zhong Yao Za Zhi 16: 524-526, 573-574, 1991.
5. Luo SR and Li T: Determination of naphthaquinones in tissue cultured Zicao. Yao Xue Xue Bao 26: 953-955, 1991.
6. Luo SR and Li T: Determination of naphthaquinone in Zicao. Zhongg Zhong Yao Za Zhi 17: 552-554, 1992.
7. Lee H and Lin JY: Antimutagenic activity of extracts from anticancer drugs in Chineses medicine. Mutat Res 204: 229-234.
8. Guo XP, Zhang XY and Zhang SD: Clinical trial on the effects of shikonin mixture on later lung cancer. Zhong Xi Yi Jie He Za Zhi 11: 598-599, 580, 1991.
9. Vineis P, Malats N and Lang M: Metabolic polymorphisms and susceptibility to cancer. IARC Scientific Publications No. 148. Lyon: IARC. 1999.
10. Dybing E and Huitfeldt MS: Species differences in carcinogen metabolism and interspecies extrapolation. IARC Scientific Publications 116: 501-522, 1992.
11. Vineis P and Pirastu R: Aromatic amines and cancer. Cancer Causes and Control 8: 346-355, 1997.
12. Miller EC and Miller JA: Search for the ultimate chemical carcinogens and their reaction with cellular macromolecules. Cancer 47: 2327-2345, 1981.
13. Weber WW and Hein DW: N-acetylation pharmacogenetics. Pharmacol Rev 37: 25-99, 1985.
14. Hein DW: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507: 65-77, 2002.
15. Cartwright RA, Glashami RW, Rogers HJ et al: Bladder cancer. Lancet 2: 842-846, 1982.
16. Lang NP, Chu DZJ, Hunter CF et al: Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 121: 1259-1261,1986.
17. Iletti KF, David BM, Detchon P et al: Acetylator phenotype in colorectal carcinoma. Cancer Res 47: 1466-1469, 1987.
18. Chung JG, Levy GN and Webber WW: Distribution of 2-aminoflurene and p-aminobenzoic acid N-acetyltransferase activity in tissues of C57BL/6J rapid and B6.A-NATs slow acetylator congenic mice. Am Soc Pharmacol Exper Therap 21 (6): 1057-1063, 2000.
19. Chung JG: Paeonol promotion of DNA adduct formation and arylamines N-acetyltransferase activity in human colon tumour cells. Food Chem Toxicol 37: 327-334, 1999.
20. Chung JG, Yeh KT, Wu SL et al: Novel transmembrane GPTase of non-small cell lung cancer identified by MRNA differential display. Cancer Res 61: 8873-8879, 2001.
21. Ponte P, Ng SY, Engel J et al: Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 12: 1687-1696, 1984.
22. Blum M, Grantum DM, McBride W et al: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 9: 193-203, 1990.
23. Cleland WW: The statistical analysis of enzyme kinetics data. Adv Enzymol 29: 1-32,1976
24. Parkin DM, Whelan SL, Ferlay J et al: Cancer incidence in five continents, Vol. VII, IARC Scientific Publications No. 143, Lyon: IRAC 1997.
25. Yu MC, Skipper PL, Tannenbaum SR et al: Arylamine exposures and bladder cancer risk. Mutat Res 506-507: 21-28, 2002.
26. Autrup H: Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 464: 65-76, 2000.
27. Hirvonen A: Polymorphisms of xenobiotic-metabolising enzymes and susceptibility to cancer. Environ Hlth Perspect, 107 Suppl 1: 34-47, 1999.
28. Gross M, KruisselbrinK T, Anderson K et al: Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomark Prev 8: 683-692, 1999.
29. Hirvoven A: Polymorphic NATs and cancer predisposition. In: Vineis P, Malats N, Lang M, D'Errico A, Caporsa N, Cuzick J, Boffeta P, editors. Metabolic Polymorphism and Susceptibility to Cancer. Lyon: IARC Scientific Publications No. 148: 251-270, 1999.
30. Bell DA, Stephens EA, Castranio T et al: Polyadenylation polymorphismin in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55: 3537-3542, 1995.
31. Bell DA, Taylor JA, Butler MA et al: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new-acetylator allele common in African-Americans. Carcinogenesis 14: 1689-1692, 1995.
32. Hein DW, Doll MA, Fretland AJ et al: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev 9: 29-42, 2000.
33. Hein DW: N-acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol Lett 112-113: 349-356, 2000.
34. Grant DM, Blum M, Beer M et al: Monomorphic and polymorphic human arylamine N-acetyltransferase: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39: 184-191, 1991.
35. Minchin RF, Reeves PT, Teitel CH et al: N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferase expressed in COS-1 cells. Biochem Biophys Res Commun 185: 839-844, 1992.
36. Thorgeirsson SS, Glowinski IB and McManus ME: Metabolism, mutagenicity, carcinogenicity of aromatic amines. In: Hodgson J, Bend J, Philpot RM (Editors). Reviews in Biochemical Toxicity, Vol. 6, Elsevier/North Holland Biomedical Press, New York, pp. 349-386, 1983.
37. Ferriola PC, Cody V and Middleton JE: Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol 15: 1617-1624, 1989.
38. Hayes MA, Roberts E, Safe SH et al: Influences of different polychlorinated biphenyls on cytocidal, mitoinhibitory, and nodule-selecting activities of N-2-fluorenylacetamide in rat liver. JNCI 76: 683-690,1986.
39. Smith G, Stanley LA, Sim E et al: Metabolic polymorphisms and cancer susceptibility. Cancer Surv 25: 27-65, 1995.
40. Sankawa U, Ebizuka Y, Miyazaki T et al: Antitumor activity of shikonin and its derivatives. Chem Pharm Bull (Tokyo) 25: 2392-2395, 1977.
41. Sankawa U, Otsuka H, Katoaka Y et al: Antitumor activity of shikonin, alkannin and their derivatives. II. X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives. Chem Pharm Bull (Tokyo) 29: 116-122, 1981.
42. Bhalla K, Ibrado AM, Tourkina E et al: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563-568, 1993.
43. Lu G and Liao J: Detection of the anti-cancer biological effect of naphthoquinone pigment-LIII. Zhong Xi Yi Jie He Za Zhi 10: 422-425, 390, 1990.
44. Yoon Y, Kim YO, Lim NY et al: Shikonin,an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med 65: 532-535, 1999.
45. Kim SH, Kang IC, Yoon TJ et al: Antitumour activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S33. Cancer Lett 172: 171-175, 2001.
46. Wang JC: DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985.
47. Withoff S, De Jong S, De Vries EG et al: Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance. Anticancer Res 16: 1867-1880, 1996.
48. Wang JC: DNA topoisomerases: from a laboratory curiosity to subject in cancer chemotherapy. NCI Monogr 4: 3-6, 1987.
49. Fujii N, Yamashita Y, Arima Y et al: Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. Antimicrob Agents Chemother 36: 2589-2594, 1992.
50. Gaddipati JP, Mani H, Shefali R et al: Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by shikonin analogue 93/637 (SA). Anticancer Res 20: 2547-2552, 2000.
51. Yoshimi N, Wang A, Morishita Y et al: Modifying effects of fungal and herb metabolites on azoxymethane-induced intestinal carcinogenesis in rats. Jpn J Cancer Res 83: 1273-1278, 1992.
52. Folkman J, Watson K, Ingber D et al: Induction of angiogenesis during the transition from hyperplasia to neoplaisa. Nature 339: 58-61, 1989.
53. Hisa T, Kimura Y, Takata K et al: Shikonin, an ingredient of Lithospermum erythrorhizon, inhibit angiogenesis in vivo and in vitro. Anticancer Res 18, 2A: 783-790, 1998.
54. Levy GN, Chung JG and Weber WW: 2-Aminofluorene metabolism and DNA adduct formation by mononuclear leukocytes from rapid and slow acetylator mouse strains. Carcinogenesis 15: 353-357,1994.
55. Zubay GL, Parson WW and Vance DE: Principles of Biochemistry. pp.135-153. Wm. C. Brown Publishers, 1995.